Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Promyelocytic Leukemia
and you are
between 14 and 70
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The investigators design a multicenter randomized controlled trial to prove that RIF plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the patients with non-high-risk APL.

Provided treatments

  • Drug: Realgar-Indigo naturalis formula
  • Drug: all-trans retinoic acid
  • Drug: Arsenic trioxide
  • Drug: Hydroxyurea
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02899169. The sponsor of the trial is First Affiliated Hospital Xi'an Jiaotong University and it is looking for 110 volunteers for the current phase.
Official trial title:
Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)